SYNCOM FORMULATIONS (INDIA)
|
|
BOM : 524470     NSE : SYNCOMF     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Feb 28,2025 |
Price(EOD): ₹ 15.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 1,442.90 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SYNCOM FORMULATIONS (INDIA) | -9.7% | -13% | 7.7% |
SUN PHARMACEUTICAL INDUSTRIES | -3% | -8.7% | 4.1% |
DIVIS LABORATORIES | -4.7% | -4.5% | 58.5% |
CIPLA | -4.3% | -3.2% | -3.2% |
TORRENT PHARMACEUTICALS | -3% | -12.3% | 13.8% |
DR REDDYS LABORATORIES | -3% | -6.5% | -12.7% |
MANKIND PHARMA | -1.6% | -8% | 9.4% |
ZYDUS LIFESCIENCES | -1% | -8.1% | -5.9% |
LUPIN | NA | -7.7% | 16.6% |
FUNDAMENTAL ANALYSIS OF SYNCOM FORMULATIONS (INDIA)
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SYNCOM FORMULATIONS (INDIA)
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
36.86
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 39.15 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 5.01
P/B Calculated based on Book Value of Rs 288.14 Cr
[Latest Year - Mar2024 - Consolidated Results ] 3.68
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 391.68 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
70% -16% -14% |
SHARE PRICE MOMENTUM OF SYNCOM FORMULATIONS (INDIA)
SYNCOM FORMULATIONS (INDIA) vs SENSEX
DEBT OF SYNCOM FORMULATIONS (INDIA)
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.25 0.32 0.27 0.28 |
0.25 0.32 0.27 0.28 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SYNCOM FORMULATIONS (INDIA)
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SYNCOM FORMULATIONS (INDIA)
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
24.65% 21.12% 16.24% 17.04% |
95.78% 100.16% 84.37% 85.65% |
QtrlyTrend |
8 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
SYNCOM FORMULATIONS (INDIA) related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | -2.1% | -3.2% | -0.6% |
BSE HEALTHCARE | -5.1% | -7.1% | 7.7% |
BSE MIDSMALLCAP | -6% | -10.6% | -4.7% |
BSE SMALLCAP | -6.5% | -12.2% | -6.4% |
You may also like the below Video Courses
FAQ about SYNCOM FORMULATIONS (INDIA)
Is SYNCOM FORMULATIONS (INDIA) good for long term investment?
As on Feb 28,2025, the Fundamentals of SYNCOM FORMULATIONS (INDIA) look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of SYNCOM FORMULATIONS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SYNCOM FORMULATIONS (INDIA) UnderValued or OverValued?
As on Feb 28,2025, SYNCOM FORMULATIONS (INDIA) is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) ?
As on Feb 28,2025, the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) is Rs. 17.84 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 9.02
Fair Value [Median EV / Sales Model] : Rs. 18.28
Fair Value [Median Price / Sales Model] : Rs. 17.84
Estimated Median Fair Value of SYNCOM FORMULATIONS (INDIA) : Rs. 17.84
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.